Related Experiment Video
Updated: Feb 27, 2026
Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
Early Diagnosis and Treatment of Lennox-Gastaut Syndrome
Trevor Resnick1,2, Raj D Sheth3,4
11 Department of Neurology and Comprehensive Epilepsy Program, Brain Institute, Nicklaus Children's Hospital, Miami, FL, USA.
Insights
Lennox-Gastaut syndrome (LGS) is a severe childhood epilepsy impacting brain development. Early treatment is advised even before a full diagnosis due to diagnostic complexities and potential for improved outcomes.
Area of Science:
- Pediatric Neurology
- Epileptology
Background:
- Lennox-Gastaut syndrome (LGS) is a severe epilepsy syndrome with significant morbidity and mortality.
- It typically manifests between ages 3-5 years, coinciding with critical brain development.
- LGS presents with diverse clinical features, complicating diagnosis.
Purpose of the Study:
- To highlight the diagnostic challenges of Lennox-Gastaut syndrome.
- To emphasize the importance of early intervention in managing LGS.
- To inform clinicians about considering treatment even before a definitive diagnosis.
Main Methods:
- Review of clinical presentation and diagnostic criteria for LGS.
- Discussion of differential diagnosis complexities.
- Analysis of the impact of delayed diagnosis on patient outcomes.
Main Results:
- Diagnosis of LGS relies on a triad: multiple seizure types, cognitive impairment, and specific EEG findings.
- Varied presentations and overlap with other epilepsies complicate accurate and timely diagnosis.
- Early treatment initiation is recommended due to the potential for improved outcomes.
Conclusions:
- Clinicians should suspect LGS based on presenting symptoms, even if the full diagnostic triad is not yet evident.
- Prompt consideration of treatment can mitigate the severe consequences of LGS.
- Addressing diagnostic complexities is crucial for effective LGS management.
Abstract:
Lennox-Gastaut syndrome (LGS) is a severe form of childhood-onset epilepsy associated with high morbidity and mortality. The peak period for manifestations of Lennox-Gastaut syndrome is between ages 3 and 5 years, a time of critical brain development and corresponding vulnerability to the electroclinical dysfunction arising from Lennox-Gastaut syndrome. Diagnosis is based on a triad of symptoms: multiple seizure types, cognitive impairment, and slow spike-and-wave pattern on electroencephalography. In practice, Lennox-Gastaut syndrome presentation is diverse, and there may be a delay between initial symptoms and emergence of the full triad of clinical features. Additionally, differential diagnosis is complicated by the resemblance of Lennox-Gastaut syndrome to other forms of epilepsy and by the need for varied diagnostic techniques requiring specific clinical skills. Because diagnosis is complex and early intervention may lead to improved outcomes, clinicians should consider treatment when Lennox-Gastaut syndrome symptoms are present, even in the absence of a formal diagnosis.
More Related Videos
09:57Author Spotlight: Advancing Pediatric Epilepsy Surgery in Children Through Novel Biomarkers and Enhanced Localization
Published on: September 20, 2024
06:04Author Spotlight: Studying Clinical Characters and Epilepsy Outcomes After Frontal Disconnection in Patients with MOGHE
Published on: August 16, 2024
Related Concept Videos
01:14Antiepileptic Drugs: Glutamate Antagonists
01:24Mania and Antimanic Drugs: Overview
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
01:22Alzheimer's Disease: Treatment
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...